Clover Health Investments Q2 Earnings Call Highlights
Clover Health Investments (CLOV) reported Q2 adjusted EBITDA of $41 million and GAAP net income of $28 million. For the first half of 2026, it posted $81 million adjusted EBITDA and $55 million GAAP net income, with $443 million cash and investments and no debt. The company raised 2026 guidance to $2.92B-$3.0B revenue and $70M-$85M adjusted EBITDA, and discussed cohort maturation and 4.5-star ratings for 2027.
How this was made
The 30-second read
Why it matters
The guidance raise and improved cohort economics are likely to be the primary drivers for forward estimates, while the CMS appeal introduces a discrete regulatory/payment risk for 2027.
Market read
Traders can update Clover’s 2026 revenue and profitability expectations based on the raised guidance ranges and assess 2027 payment-rate risk tied to CMS’s appeal.
What to watch
CMS intends to appeal the District Court decision affecting 2027 star ratings, creating potential payment-rate uncertainty even though Clover expects 4.5-star enrollment next year.
Background
Clover reported Q2 results and used the earnings call to update 2026 guidance, discuss cohort maturation and medical-cost trends, and address the 2027 Medicare Advantage star-rating recalculation tied to a court order.
Ticker impact
Clover raised full-year 2026 guidance, including revenue $2.92B to $3.0B and adjusted EBITDA $70M to $85M, after Q2 results.
Likely near-term positive bias as guidance and star-rating/payment expectations improve forward cash-flow expectations.
The article discloses multiple forward-looking datapoints (raised guidance ranges, cohort maturation economics, and 2027 4.5-star enrollment/payment expectation) that can drive re-rating, though it also notes seasonality and an ongoing CMS appeal risk.
Market effects
Medicare Advantage plan operators may see read-across interest in cohort maturation, medical-cost trend management, and star-rating/payment mechanics.
Mentions competitive disruption assumptions in Clover’s New Jersey and Georgia markets, relevant to regional MA competitive dynamics.
Limited, as the disclosure is company-specific to Clover’s MA economics and CMS star-rating/payment process.
Counterpoint
Despite raised guidance, the company expects seasonally typical adjusted EBITDA losses in Q4 and notes additional claims experience is still expected, which could temper margin confidence.
Key entities
- companyClover Health Investments
Technology-driven Medicare Advantage provider reporting Q2 results and raising 2026 guidance.
- regulatorCenters for Medicare & Medicaid Services (CMS)
Recalculated Medicare Advantage star ratings for 2027 following a court order and filed notice to appeal.
- executiveThornton
Management speaker cited on cash flow, medical-cost trends, and guidance rationale.
- executiveToy
Management speaker cited on cohort maturation, 4.5-star rating implications, and AI expansion plans.
